SubHero Banner
Text

Keytruda® (pembrolizumab) – Expanded indications

June 11, 2019 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with platinum and fluorouracil (FU), for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC); and as a single agent, for the first line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

Download PDF